Accuray Incorporated reported a net revenue of $401.9 million for the fiscal year ended June 30, 2026, a decrease of 12% compared to $458.5 million in the prior fiscal year. This decline was primarily driven by a 27% decrease in product revenue, which fell to $172.7 million from $237.6 million, largely due to reduced system shipment volumes in the China region. Services revenue saw a modest increase of 4% to $229.2 million from $220.9 million, attributed to a growing installed base and higher contract renewal rates. The company's gross profit decreased by 24% to $111.5 million, with gross profit as a percentage of net revenue declining to 27.7% from 32.1%, impacted by non-IEEPA tariff expenses and an unfavorable product and region mix, particularly fewer CyberKnife System shipments to China.

The company's operating expenses remained relatively stable, decreasing by 1% to $137.9 million for the fiscal year ended June 30, 2026, compared to $139.1 million in the prior year. This stability was largely due to cost reduction actions implemented under the company's Transformation Plan and FY26 Restructuring Plan, which resulted in a 21% decrease in research and development expenses and an 11% decrease in selling and marketing expenses. General and administrative expenses also decreased by 5%. However, the company recorded $16.2 million in restructuring charges during the fiscal year, primarily related to severance and employee-related costs, third-party implementation, and asset impairments.

Accuray experienced a net loss of $49.2 million for the fiscal year ended June 30, 2026, a significant increase from a net loss of $1.6 million in the prior fiscal year. This widened net loss was influenced by the decrease in net revenue, lower gross profit, increased interest expense of $32.9 million compared to $13.0 million, and the aforementioned restructuring charges. The company's income from its equity method investment in the joint venture decreased by 76% to $1.1 million, reflecting reduced revenues from the JV.

Looking ahead, Accuray continues to navigate a challenging macroeconomic and geopolitical environment, including ongoing supply chain disruptions, inflation, and tariff uncertainty, particularly concerning trade with China. These factors are expected to continue impacting gross margins and cash flow through at least fiscal year 2027. The company has implemented a comprehensive Transformation Plan and FY26 Restructuring Plan aimed at improving operating margins, enhancing organizational agility, and positioning the company for sustainable growth. Accuray also recently completed a significant financing transaction, including the issuance of Series A Convertible Preferred Stock and modifications to its credit facilities, to enhance liquidity and financial flexibility. The company believes it has sufficient cash resources to fund operations for at least the next twelve months, but acknowledges the ongoing uncertainties in the global economic landscape.

About ACCURAY INC

Accuray Incorporated is a radiation therapy company specializing in advanced treatment solutions for cancer and other disorders. Its key products, including the CyberKnife and TomoTherapy platforms, utilize innovative technologies like AI-driven motion tracking for precise, personalized treatments. With a focus on enhancing patient care and expanding market reach, Accuray targets healthcare providers globally, aiming to improve treatment efficiency and outcomes while addressing significant unmet needs in oncology.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov